ForexTV Small Business Resources -Forextv.com
Shares of Amarin Corp. are up about 6% in premarket trading after a U.S. Food and Drug Administration advisory committee on Thursday voted 16-0 in favor of a broader label for the company’s prescription fish oil-derived pill. The FDA is expected to decide on the new label by Dec. 28. If approved, Vascepa would be marketed as a treatment to lower the risk of cardiovascular events, like heart attacks or strokes. This label expansion would also likely expand the size of the patient population from 4 million to more than 40 million, according to Maxim Group analyst Jason McCarthy. “In our view, the market has the potential to be statin-like in size,” he wrote in a note Friday. Stifel estimates $3 billion peak sales of Vascepa. Shares of Matinas BioPharma Holdings , which is developing a similar drug to Vascepa, also rose in premarket market trading, up 14%. Amarin stock has jumped 57.9% year-to-date, while the S&P 500 is up 23%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
- Dark day for workers as thousands lose jobs including 15,000 at Boeing rival Airbus. - July 2, 2020
- The extra $600 Americans receive in unemployment benefits ends this month — here’s what else is on the table - July 2, 2020
- Dispatches from a Pandemic: ‘You feel like you’re being social — and responsible’: Meet the people who are turning garages into mini-bars - July 2, 2020
